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Amyloidosis is not the only renal involvement in FMF
pediatric patients.
The purpose of this study is to evaluate the renal
biopsy results and look for the trends over the time in
FMF children.
Methods
From 1993 to 2014 renal biopsies were done in 83 FMF
patients with renal involvement (mean age 12±4 year;
range 2.2-18; 45 males) at “Arabkir” MC -ICAH. The
diagnosis of FMF based on international clinical criteria
and genetic analysis.
Results
Renal amyloidosis (RA) revealed in 56 patients out of 83
(67%), who actually had never been treated by colchicine
and FMF as well as amyloidosis were diagnosed initially
on admission.
32.5% of FMF patients had other nephropathies: mini-
mal change nephrotic syndrome (7); focal segmental glo-
merulosclerosis (7); acute postinfection glomerulonephritis
(6); IgA nephropathy/Henoch-Schönlein nephritis (2/2);
membranoproliferative glomerulonephritis type I (1); thin
basement membrane disease and tubulointerstitial nephri-
tis (1 of each).
Since 2003 the long-term program on “Early diagnosis
and treatment of FMF in children in Armenia” has been
implemented at National Pediatric Centre of FMF (NPC
FMF) and more than 2700 children with FMF got regular
colchicine therapy up to now. This resulted in dramatic
decline of frequency of RA from 2003 to 2014: only two
cases of amyloidosis have been registered in NPC FMF,
while, prior to the regular colchicine treatment 16.2 % of
FMF patients developed amyloidosis.
In the past 10 years a tendency of lowering the number
of amyloidosis in children has been observed throughout
Armenia as well (42% in 1993-2003 vs 25% in 2004-
2014). Moreover during last 5 years there were only 6
pediatric cases of renal amyloidosis. Most of the patients
had never received colchicine therapy.
Conclusion
• In the last 10 years RA frequency has markedly
decreased at NPC FMF due to the long-term pro-
gram on improving of early diagnosis and regular
colchicine treatment in FMF children. This program
should be continued as the number of FMF patients
is constantly increasing and amyloidosis is still a
problem in children in Armenia.
• Amyloidosis is not the only type of renal involve-
ment in FMF.
• The biopsy is mandatory in any case of renal
involvement.
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